The study also showed that patients with IDH1 wildtype cystic glioblastoma did not show a survival benefit from current SOC (p ​= ​0.99) while those with non-cystic IDH1 wildtype showed a positive survival benefit (p ​< ​0.0001). The gene discussed is IDH1; the disease is glioblastoma.